[go: up one dir, main page]

MX2013007807A - Emulsiones de aceite/agua que comprenden alcanos semifluorados. - Google Patents

Emulsiones de aceite/agua que comprenden alcanos semifluorados.

Info

Publication number
MX2013007807A
MX2013007807A MX2013007807A MX2013007807A MX2013007807A MX 2013007807 A MX2013007807 A MX 2013007807A MX 2013007807 A MX2013007807 A MX 2013007807A MX 2013007807 A MX2013007807 A MX 2013007807A MX 2013007807 A MX2013007807 A MX 2013007807A
Authority
MX
Mexico
Prior art keywords
semifluorated
alkans
understanding
oil
water emulsions
Prior art date
Application number
MX2013007807A
Other languages
English (en)
Other versions
MX353154B (es
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Guenther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2013007807A publication Critical patent/MX2013007807A/es
Publication of MX353154B publication Critical patent/MX353154B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona composiciones líquidas en la forma de emulsiones físicamente estables que comprenden un alcano semifluorado. El alcano semifluorado está comprendido en la fase dispersa, la cual puede incluir también un ingrediente farmacéutico activo. Uno de los ingredientes activos preferido es propofol. Las composiciones son, opcionalmente, esterilizables por calor y pueden usarse para aplicaciones de producto farmacéuticas o cosméticas y administrarse tópicamente, intravenosamente o vía otras rutas.
MX2013007807A 2011-01-04 2012-01-03 Emulsiones de aceite/agua que comprenden alcanos semifluorados. MX353154B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150064 2011-01-04
PCT/EP2012/050043 WO2012093113A1 (en) 2011-01-04 2012-01-03 O/w-emulsions comprising semifluorinated alkanes

Publications (2)

Publication Number Publication Date
MX2013007807A true MX2013007807A (es) 2013-12-16
MX353154B MX353154B (es) 2017-12-20

Family

ID=43978091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007807A MX353154B (es) 2011-01-04 2012-01-03 Emulsiones de aceite/agua que comprenden alcanos semifluorados.

Country Status (15)

Country Link
US (6) US20140004197A1 (es)
EP (2) EP2661280B1 (es)
JP (1) JP6073244B2 (es)
KR (1) KR101910213B1 (es)
CN (1) CN103313729B (es)
AU (1) AU2012204932B2 (es)
BR (1) BR112013016661B1 (es)
CA (1) CA2819988C (es)
DK (2) DK2661280T3 (es)
ES (2) ES2675242T3 (es)
MX (1) MX353154B (es)
PL (2) PL3202421T3 (es)
PT (2) PT3202421T (es)
TR (2) TR201901309T4 (es)
WO (1) WO2012093113A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
EP3192501B1 (en) 2011-05-25 2020-05-13 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
GB2511028A (en) * 2012-12-18 2014-08-27 Univ Manchester Metropolitan Nano emulsions, methods of forming the same and uses thereof
EP2783703A1 (en) * 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
AU2015227307A1 (en) 2014-03-03 2016-10-13 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019012791A2 (pt) 2016-12-23 2019-12-03 Novaliq Gmbh composição oftálmica para o tratamento da doença do olho seco
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
KR102404412B1 (ko) 2018-09-27 2022-05-31 노바리크 게엠베하 국소 선스크린 제제
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
MX2022002667A (es) 2019-09-06 2022-04-07 Novaliq Gmbh Composicion oftalmica para el tratamiento de uveitis.
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache
FR3112475B1 (fr) 2020-07-20 2023-11-10 Naos Inst Of Life Science formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires
AU2021426502A1 (en) * 2021-02-05 2023-08-17 Epalex Corporation Fospropofol methods and compositions
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) * 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
AU2004293027A1 (en) * 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
TWI368505B (en) * 2005-05-24 2012-07-21 Wyeth Corp Versatile high load concentrate compositions for control of ecto-parasites
KR20080043793A (ko) 2005-08-05 2008-05-19 바라트 쎄럼스 앤드 백신스 리미티드 방부 효능을 갖는 정맥 프로포폴 에멀젼 조성물
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej

Also Published As

Publication number Publication date
US20230139672A1 (en) 2023-05-04
WO2012093113A1 (en) 2012-07-12
AU2012204932A1 (en) 2013-07-04
US20190224123A1 (en) 2019-07-25
EP3202421B1 (en) 2018-03-28
US20250345276A1 (en) 2025-11-13
US20140004197A1 (en) 2014-01-02
PL3202421T3 (pl) 2018-10-31
PT2661280T (pt) 2019-02-25
AU2012204932B2 (en) 2017-02-23
TR201901309T4 (tr) 2019-02-21
PL2661280T3 (pl) 2019-05-31
CN103313729A (zh) 2013-09-18
EP2661280A1 (en) 2013-11-13
CN103313729B (zh) 2016-11-09
KR101910213B1 (ko) 2018-12-19
KR20140003477A (ko) 2014-01-09
US20170216204A1 (en) 2017-08-03
MX353154B (es) 2017-12-20
DK3202421T3 (en) 2018-07-16
CA2819988A1 (en) 2012-07-12
ES2675242T3 (es) 2018-07-09
US20200360285A1 (en) 2020-11-19
BR112013016661A2 (pt) 2016-10-04
BR112013016661B1 (pt) 2021-08-03
JP2014501270A (ja) 2014-01-20
EP2661280B1 (en) 2018-11-21
ES2711760T3 (es) 2019-05-07
DK2661280T3 (en) 2019-03-04
TR201808752T4 (tr) 2018-07-23
PT3202421T (pt) 2018-07-03
EP3202421A1 (en) 2017-08-09
JP6073244B2 (ja) 2017-02-01
CA2819988C (en) 2019-11-12

Similar Documents

Publication Publication Date Title
MX2013007807A (es) Emulsiones de aceite/agua que comprenden alcanos semifluorados.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
DOP2015000274A (es) Compuestos químicos
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
PE20180038A1 (es) Composiciones farmaceuticas topicas
CO6680658A2 (es) Agonista de gpr 40
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
WO2012160179A3 (en) Topical pharmaceutical composition based on semifluorinated alkanes
DOP2015000170A (es) Compuestos químicos
BR112014026117A2 (pt) composições para higiene pessoal
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX384073B (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX387217B (es) Composiciones de solución sólida para aines.
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
NZ702472A (en) Oil/water-emulsion-type topical compositions containing a retinoid
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
MX2017014235A (es) Formulaciones de emulsion estable de compuestos volatiles encapsulados.
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2019006843A (es) Inhibidor de cdk4/6.

Legal Events

Date Code Title Description
FG Grant or registration